Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling.
Berry
Mark F
MF
Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Woo
Y Joseph
YJ
Pirolli
Timothy J
TJ
Bish
Lawrence T
LT
Moise
Mireille A
MA
Burdick
Jeffrey W
JW
Morine
Kevin J
KJ
Jayasankar
Vasant
V
Gardner
Timothy J
TJ
Sweeney
H Lee
HL
D000818:Animals; D000068800:Etanercept; D006321:Heart / Q000502:physiology; D006333:Heart Failure / Q000378:metabolism; D006439:Hemodynamics; D007074:Immunoglobulin G / Q000494:pharmacology*; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D020257:Ventricular Remodeling / Q000187:drug effects*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D020781:Matrix Metalloproteinase 1; D000068800:Etanercept